Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at https://www.leidos.com/about/companies/leidos-biomedical-research.
The Cancer Research Technology Program (CRTP) develops and implements emerging technology, cancer biology expertise and research capabilities to accomplish NCI research objectives. The CRTP is an outward-facing, multi-disciplinary hub purposed to enable the external cancer research community. A major focus of the CRTP is the NCI RAS Initiative with the goal to discover new therapeutic interventions against RAS-driven cancers. In addition, the CRTP hosts the Nanotechnology Characterization Laboratory (NCL) which performs and standardizes preclinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics and diagnostics, and the Antibody Characterization Lab (ACL) which characterizes monoclonal antibodies or other renewable affinity binding reagents for use in cancer related research. CRTP scientists also work collaboratively with intramural NCI investigators to provide research technologies and expertise.
The structural biology group in the RAS initiative focuses on structural analysis of KRAS mutants and biologically relevant KRAS activator/effector complexes in support of drug discovery efforts and to further understand the biochemistry of RAS proteins. We are looking for a highly motivated post-doctoral fellow to join our group. Highly motivated candidates who recently obtained a Ph.D. with a strong background in biochemistry, biophysics and structural biology are encouraged to apply. This post-doc will work closely with the protein production group and carry out structural studies on oncogenic KRAS complexed with effectors, GAPs, regulators and small molecules. We use X-ray crystallography, NMR, molecular modeling, and other biophysical techniques for structural characterization.
The candidate will be expected to be able to participate in experimental design and to independently conduct experiments in a priority-driven environment. The candidate should have the ability to act both independently and as a part of the RAS team in pursuit of specific research goals and objectives. The structural biology group in the RAS initiative works very closely with the biochemistry and biophysics group, and is well equipped with crystallization robotics, in-house X-ray generator, and has regular access to the synchrotron beamline at Argonne.
Possession of a doctoral degree from an accredited college/university according to the Council for Higher Education Accreditation (CHEA) in a field related to structural biology, biochemistry, biophysics or computational biology
Foreign degrees must be evaluated for U.S. equivalency
Demonstrated proficiency in protein biochemical and biophysical characterization
Ability to act both independently and as a part of the RAS team in pursuit of specific research goals and objectives
Ability to conduct experiments and evaluate results independently
Experience in crystallization and structure determination of protein-ligand and protein-protein complexes
Experience working with small GTPases or RAS-related effector proteins and Knowledge of molecular dynamics simulations and protein-ligand docking.